Compare KEQU & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEQU | MOLN |
|---|---|---|
| Founded | 1906 | 2004 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 106.3M | 170.5M |
| IPO Year | 1995 | 2021 |
| Metric | KEQU | MOLN |
|---|---|---|
| Price | $34.45 | $4.18 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $8.38 |
| AVG Volume (30 Days) | ★ 1.6K | 1.2K |
| Earning Date | 03-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.22 | N/A |
| Revenue | ★ $138,558,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $374.07 |
| P/E Ratio | $10.88 | ★ N/A |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $33.27 | $3.53 |
| 52 Week High | $46.70 | $5.36 |
| Indicator | KEQU | MOLN |
|---|---|---|
| Relative Strength Index (RSI) | 33.70 | 48.08 |
| Support Level | $33.49 | $4.13 |
| Resistance Level | $35.35 | $4.19 |
| Average True Range (ATR) | 0.95 | 0.07 |
| MACD | -0.30 | -0.03 |
| Stochastic Oscillator | 34.29 | 18.33 |
Kewaunee Scientific Corp is engaged in the design, manufacture, and installation of laboratory, healthcare, and technical furniture and infrastructure products. Its products include steel and wood casework, fume hoods, adaptable modular systems, movable workstations, stand-alone benches, biological safety cabinets, epoxy resin work surfaces, and sinks. The company operates through two reportable segments: Lab Products Group (LPG), which designs, manufactures, and installs scientific and technical furniture, including steel and wood laboratory cabinetry, fume hoods, flexible systems, work surfaces, workstations, workbenches, and computer enclosures, and the International segment.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.